rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Seer, Inc.

SEER · Nasdaq

Health CareLife-science toolsIn trend

SEER stood above a rising 150-day average in 14 of the last 52 weekly readings, including each of the last 4 weeks. It is 2.5% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+1 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
4 in a row
Industry in uptrend
52% +1 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$309K
Officials’ trades on record
0
Institutions holding
54 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 14 of 52 weeks.

21 Apr – 20 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$123K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months7
Buyers · sellers0 · 3
WhoDidSharesTraded
David R. HornPRESIDENT & CFOsold7,309at $2.0318 Aug 2026filed 19 Aug 2026
Dipchand NisharDirectorsold10,660at $2.188 Jul 2026filed 10 Jul 2026
David R. HornPRESIDENT & CFOsold7,303at $1.6920 May 2026filed 21 May 2026
Omid FarokhzadCEO AND CHAIRsold24,385at $1.9918 Feb 2026filed 19 Feb 2026
David R. HornPRESIDENT & CFOsold7,743at $1.9918 Feb 2026filed 19 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders54+3 on the quarter
New · exited9 · 6
Reported value$30.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
SOFTBANK GROUP CORP.unchanged · filed 14 Aug 20265,135,383$8.5M00.0%
Siren, L.L.C.unchanged · filed 13 Aug 20262,458,673$4.1M00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,831,058$3.0M-127,938−6.5%
BlackRock, Inc.reduced · filed 7 Aug 20261,428,405$2.4M-393,199−21.6%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026985,500$1.6M+8,812+0.9%
NANO CAP NEW MILLENNIUM GROWTH FUND L Punchanged · filed 14 Aug 2026825,000$1.4M00.0%
CITADEL ADVISORS LLCnew · filed 14 Aug 2026519,310$862K+519,310
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 2026492,298$817K-19,300−3.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026460,430$765K+37,453+8.9%
BRIDGEWAY CAPITAL MANAGEMENT, LLCunchanged · filed 14 Aug 2026459,443$763K00.0%
31 Mar 2023 – 30 Jun 2026
526781Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

David R. Horn Company insiderPRESIDENT & CFO · last 18 Aug 20260 · 22
Dipchand Nishar Company insiderDirector · last 28 Jul 20260 · 3
Isaac Ro Company insiderDirector · last 28 Jul 20260 · 0
Meeta Gulyani Company insiderDirector · last 28 Jul 20260 · 0
Nicolas H. Roelofs Company insiderDirector · last 28 Jul 20260 · 0
Robert Langer Company insiderDirector · last 28 Jul 20260 · 0
Terrance McGuire Company insiderDirector · last 28 Jul 20261 · 0
Anthony R. Bazarko Company insiderChief Commercial Officer · last 8 May 20260 · 0
Omid Farokhzad Company insiderCEO AND CHAIR · last 18 Feb 20261 · 13
David Hallal Company insiderDirector · last 12 Jun 20240 · 0
Rachel E. Haurwitz Company insiderDirector · last 12 Jun 20240 · 0
Elona Kogan Company insiderCHIEF LEGAL OFFICER · last 22 Feb 20240 · 4

Same industry

OABI OmniAbLeading+75%
TXG 10x GenomicsLeading+61%
AVTR AvantorLeading+48%
ILMN IlluminaLeading+46%
RVTY RevvityLeading+39%
MASS 908 DevicesLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202551.1%
Operating profit marginFY 2025 · to 31 Dec 2025-470%
Free cash flow marginFY 2025 · to 31 Dec 2025-279%
Return on capital employedFY 2025 · to 31 Dec 2025-27.8%
Research spendFY 2025 · to 31 Dec 2025265%
Cash and equivalentsFY 2025 · to 31 Dec 2025$47.3M
Free cash flowFY 2025 · to 31 Dec 2025−$46.2M

Analyst forecasts

No analyst forecasts yet.